ENTRY       D03150                      Drug
NAME        Bortezomib (JAN/USAN/INN);
            Velcade (TN)
PRODUCT     BORTEZOMIB (Dr.Reddy's Laboratories)
            BORTEZOMIB (FOSUN PHARMA USA)
            BORTEZOMIB (Fresenius Kabi USA)
            BORTEZOMIB (Hospira)
            BORTEZOMIB (MAIA Pharmaceuticals)
            VELCADE (Takeda Pharmaceuticals America)
  GENERIC   BORTEZOMIB (Apotex Corp)
            BORTEZOMIB (Athenex Pharmaceutical Division)
            BORTEZOMIB (Baxter Healthcare Corporation)
            BORTEZOMIB (BluePoint Laboratories)
            BORTEZOMIB (BluePoint Laboratories)
            BORTEZOMIB (BluePoint Laboratories)
            BORTEZOMIB (Dr.Reddy's Laboratories)
            BORTEZOMIB (Fresenius Kabi USA)
            BORTEZOMIB (Hikma Pharmaceuticals USA)
            BORTEZOMIB (Hospira)
            BORTEZOMIB (Ingenus Pharmaceuticals)
            BORTEZOMIB (Meitheal Pharmaceuticals)
            BORTEZOMIB (Novadoz Pharmaceuticals LLC)
            BORTEZOMIB (Pharmascience)
            BORTEZOMIB (Qilu Pharmaceutical)
            BORTEZOMIB (Sagent Pharmaceuticals)
            BORTEZOMIB (Sandoz)
            BORTEZOMIB (Sintetica US LLC)
            BORTEZOMIB (Zydus Lifesciences Limited)
            BORTEZOMIB (Zydus Pharmaceuticals USA)
FORMULA     C19H25BN4O4
EXACT_MASS  384.1969
MOL_WEIGHT  384.2372
CLASS       Antineoplastic
             DG03134  Proteasome inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01XG01
            Chemical structure group: DG03219
            Product (DG03219): D03150<JP/US> D12311<JP/US>
EFFICACY    Antineoplastic, Proteasome inhibitor
  DISEASE   Multiple myeloma [DS:H00010]
            Mantle cell lymphoma [DS:H01464]
TARGET      PSMB5 [HSA:5693] [KO:K02737]
  PATHWAY   hsa03050(5693)  Proteasome
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01X OTHER ANTINEOPLASTIC AGENTS
                L01XG Proteasome inhibitors
                 L01XG01 Bortezomib
                  D03150  Bortezomib (JAN/USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Bortezomib
                D03150  Bortezomib (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D03150  Bortezomib (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG03134  Proteasome inhibitor
               DG03219  Bortezomib
                D03150  Bortezomib
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Threonine peptidases
                PSMB5
                 D03150  Bortezomib (JAN/USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D03150
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D03150
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D03150
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D03150
            Drug groups [BR:br08330]
             Antineoplastic
              DG03134  Proteasome inhibitor
               DG03219  Bortezomib
DBLINKS     CAS: 179324-69-7
            PubChem: 17397304
            ChEBI: 52717
            PDB-CCD: BO2
            NIKKAJI: J1.921.292K
ATOM        28
            1   N1b N    22.6554  -16.2029
            2   C1c C    23.8603  -15.5194
            3   C8x C    17.8708  -16.2029
            4   C8x C    17.8708  -17.5889
            5   N5x N    19.0679  -18.2854
            6   C8x C    20.2651  -17.5889
            7   C8y C    20.2651  -16.2029
            8   N5x N    19.0679  -15.5134
            9   C5a C    21.4576  -15.5134
            10  O5a O    21.4564  -14.1276
            11  C5a C    25.0492  -16.2179
            12  N1b N    26.2724  -15.5238
            13  C1c C    27.4532  -16.2173
            14  C1b C    28.6374  -15.5453
            15  C1c C    29.7998  -16.2280
            16  C1a C    30.9930  -15.5506
            17  C1a C    29.7895  -17.6043
            18  O5a O    25.0388  -17.6038
            19  C1b C    23.8705  -14.1451
            20  C8y C    25.0967  -13.4488
            21  C8x C    26.2767  -14.1418
            22  C8x C    27.4803  -13.4586
            23  C8x C    27.4905  -12.0748
            24  C8x C    26.3105  -11.3818
            25  C8x C    25.1069  -12.0650
            26  Z   B    27.4430  -18.1578
            27  O1a O    26.2291  -18.8468
            28  O1a O    28.6261  -18.8527
BOND        29
            1     3   4 2
            2     4   5 1
            3     5   6 2
            4     6   7 1
            5     7   8 2
            6     8   3 1
            7     7   9 1
            8     9   1 1
            9     2   1 1
            10    9  10 2
            11    2  11 1
            12   11  12 1
            13   12  13 1
            14   13  14 1
            15   14  15 1
            16   15  16 1
            17   15  17 1
            18   11  18 2
            19   19  20 1
            20   20  21 2
            21   21  22 1
            22   22  23 2
            23   23  24 1
            24   24  25 2
            25   20  25 1
            26    2  19 1 #Up
            27   26  27 1
            28   26  28 1
            29   13  26 1 #Up
///
